8 recruiting, 4 unknown, 3 completed, 2 active not recruiting. 6 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Hormone-receptor-positive Breast Cancer: new trials by email Literature Review of Hormone-receptor-positive Breast Cancer trials Research Report on Hormone-receptor-positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial Tirzepatide, Letrozole (Aromatase Inhibitors) - Hormone-receptor-positive Breast Cancer, Early Breast Cancer | Phase 2 | Not yet recruiting | Universitaire Ziekenhuizen KU Leuven | 168 | 2026-08-01 | 2026-07-07 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| A Study of Revaree Plus in People With Breast Cancer Revaree Plus - Breast Cancer, Stage 0 Breast Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-20 | 2026-02-06 |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer BGB-21447, Fulvestrant, BGB-43395 - Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 120 | 2025-02-04 | 2026-09-14 |
| Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer SHR-A1921, Adebrelimab - Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2024-12-01 | 2024-12-20 |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer Abemaciclib, Radiation Therapy - Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2024-11-15 | 2026-05-28 |
| Study of XB010 in Subjects With Solid Tumors XB010, Pembrolizumab - Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer | Phase 1 | Recruiting | Exelixis | 396 | 2024-08-06 | 2026-10-15 |
| Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. Palbociclib - Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Unknown | Helwan University | 100 | 2024-07-01 | 2024-03-29 | |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC Sacituzumab govitecan - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Reshma L. Mahtani, D.O. | 75 | 2024-06-17 | 2026-08-12 |
| DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients Biospecimen Collection - HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer | Recruiting | Mayo Clinic | 100 | 2024-04-30 | 2026-06-01 | |
| BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | BeOne Medicines | 33 | 2024-04-01 | 2026-06-10 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer | Phase 1 | Active not recruiting | BeiGene | 103 | 2024-03-11 | 2026-10-20 |
| Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel - Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer | Phase 3 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 160 | 2024-01-17 | 2026-08-18 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 433 | 2023-12-01 | 2026-10-15 |
| Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer No drug - Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer | Completed | Daiichi Sankyo | 927 | 2023-07-31 | 2024-02-26 | |
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen - Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 700 | 2023-06-01 | 2023-05-18 | |
| Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors Brief Physical Activity Counselling, Structured Exercise Program - Breast Cancer Female, Hormone-receptor-positive Breast Cancer | Not applicable | Unknown | Grupo Lusófona | 122 | 2022-01-05 | 2023-05-16 |
| Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Completed | Novartis | 121 | 2020-04-06 | 2024-06-18 |
Breast Neoplasms (11) · Triple Negative Breast Neoplasms (3) · Breast Carcinoma In Situ (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Breast Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Breast Neoplasms (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Lung Diseases (2) · Lung Neoplasms (2)
Fulvestrant (4) · Letrozole (3) · Aromatase Inhibitors (2) · Specimen Handling (2) · ARX788 (1) · Amiloride (1) · Cyclophosphamide (1) · Doxorubicin (1) · Epirubicin (1) · Gonadotropin-Releasing Hormone (1) · Ovariectomy (1) · Paclitaxel (1) · Radiotherapy (1) · Tamoxifen (1) · Tirzepatide (1)
BeOne Medicines (3) · Memorial Sloan Kettering Cancer Center (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · BeiGene (1) · Daiichi Sankyo (1) · Exelixis (1) · Fudan University (1) · Grupo Lusófona (1) · Helwan University (1) · Laura Huppert, MD, BA (1) · Mayo Clinic (1) · Novartis (1) · Reshma L. Mahtani, D.O. (1) · Universitaire Ziekenhuizen KU Leuven (1)
United States (11) · China (7) · Australia (3) · Moldova (2) · New Zealand (2) · Brazil (1) · France (1) · Israel (1) · Japan (1) · Malaysia (1) · Portugal (1) · South Korea (1) · Thailand (1) · United Kingdom (1)
Chang Gong, Prof (1) · Chang Gong, docto (1) · Hongxia Wang (1) · Laura Huppert, MD (1) · Lior Braunstein, MD (1) · Patrick Neven, MD, PhD (1) · Pooja Advani, MBBS, MD (1) · Reshma L Mahtani, D.O. (1) · Shari Goldfarb, MD (1)
PMID 37407950, PMID 39799368, PMID 40957562
2023 (1)